Open Journal Systems

Cover Image

Envisioning the reversal of oncogenesis

Nivedita Lahiri, Sudeep K Lahiri

Abstract


Cancer, at different stages, is currently treated with conventional methods including chemotherapy, radiotherapy or surgery. These approaches often become ineffective for cancers that have spread aggressively in different parts of the body (metastasis). Hence, researchers have been actively investigating alternative methods to stop cancer-growth (oncogenesis) or even possibly reversing the cancer-growth (regression) without affecting the normal cells. Several approaches are used by scientists ranging from enhancing the immune system (immunotherapy) to genetic manipulations. Prophylactic vaccines are also attempted. An overview of such attempts is presented in this review. Several drugs developed at trial phases, or pre-clinical or exploratory phases are described. Many approaches show a promise of inhibiting oncogenesis, some also in its regression, thereby hinting at a possibility of finding a permanent solution to cancer in future.


Keywords


Carcinogenesis; oncogene; tumor suppressor gene; cell signaling; cell division; biomarker; target detection; immunotherapy; vaccine; targeted therapy; gene therapy; apoptosis

Full Text:

PDF

References


Union of International Cancer Control.," WHO, Geneva, 2013.

Cancer: A neglecte health problem in developing countries.," International network for Cancer treatment and research, [Online]. Available: http://www.inctr.org/about-inctr/cancer-in-developing-countries

How many different types of cancer are there ?," Cancer Research UK, [Online]. Available: http://www.cancerresearchuk.org/cancer-help/about-cancer/cancer-questions/how-many-different-types-of-cancer-are-there.

Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB: Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res 2008, 25: 2097-2116.

http://dx.doi.org/10.1007/s11095-008-9661-9

PMid:18626751 PMCid:PMC2515569

Heredity and Cancer," American Cancer Society, 2013.

Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007, 6: 287-293.

http://dx.doi.org/10.1038/nrd2251

PMid:17380152

Vazquez A: Optimization of personalized therapies for anticancer treatment. BMC Systems Biology 2013, 7:31.

http://dx.doi.org/10.1186/1752-0509-7-31

PMid:23587292 PMCid:PMC3651412

Duarte FJ: Tunable Laser Applications. CRC, New York 2009, Chapters 5-8.

Dolmans DE, Fukumura D, Jain RK : Photodynamic therapy for cancer. Nat Rev cancer 2003, 3: 380-387.

http://dx.doi.org/10.1038/nrc1071

PMid:12724736

Damodar S, Terunuma H, Abraham S, Autologous Immune Enhancement Therapy (AIET) for a case of Acute Myeloid Leukemia (AML)- Our experience. Pasrm 2006, 2006-001.

Sivaraman G, Pandian A, Abraham S : Autologous Immune Enhancement therapy for Advanced Carcinoma of Pancreas-A Case Report. PASRM 2008.

Kleinman HK: Gene therapy for antiangiogenesis. J. Natl. Cancer Inst. 2001, 93: 965–967.

http://dx.doi.org/10.1093/jnci/93.13.965

PMid:11438554

Feldser DM, Kostova KK: Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010, 468: 572-575.

http://dx.doi.org/10.1038/nature09535

PMid:21107428 PMCid:PMC3003305

Alavanja MC: Biologic damage resulting from exposure to tobacco smoke and from radon: Implication for preventive interventions. Oncogene 2002, 21: 7365-7375.

http://dx.doi.org/10.1038/sj.onc.1205798

PMid:12379879

Hecht SS: Cigarette smoking and lung cancer: Chemical mechanisms and approaches to prevention. Lancet Oncol 2002, 3: 461-469.

http://dx.doi.org/10.1016/S1470-2045(02)00815-X

de Kok TM, van Maanen JM: Evaluation of fecal mutagenicity and colorectal cancer risk. Mutat Res 2000, 463: 53-101.

http://dx.doi.org/10.1016/S1383-5742(00)00003-X

Furumoto H, Irahara M: Human papilloma virus (HPV) and cervical cancer. J Med Invest, 2002, 49: 124-1233.

PMid:12323001

Davies JA: Inverse Correlation Between an Organ's Cancer Rate and Its Evolutionary Antiquity. Organogenesis 2004 1:2: 60-63.

http://dx.doi.org/10.4161/org.1.2.1338

PMid:20140231 PMCid:PMC2816350

Some stem cells tend to be more prone to cancer than the others. [Online]. Available: http://www.regenestem.com/some-stem-cells-are-more-susceptible-to-cancer-than-others/.

Lu C, Onn A, Vaporciyan AA: Cancer of the Lung. in Holland-Frei Cancer Medicine (8th ed.) ISBN 9781607950141, People's Medical Publishing House, 2010.

Singh S, Clarke I, Terasaki M, Bonn V, Hawkins C, Squire J, Dirks P: Identification of human brain tumor initiating cells. Nature 2004, 432: 396-401.

http://dx.doi.org/10.1038/nature03128

PMid:15549107

Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, Lawton MT, McDermott MW, Parsa AT, Manueal-Garcia VJ, Berger MS, Alvarez-Buylla A: Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 2004, 427: 740-744.

http://dx.doi.org/10.1038/nature02301

PMid:14973487

Sanai N, Alvarez-Buylla A, Berger M: Neural stem cells and the origin of gliomas. N Engl J Med 2005, 353: 811–822.

http://dx.doi.org/10.1056/NEJMra043666

PMid:16120861

"Heart cancer: Is there such a thing? - MayoClinic.com"," MayoClinic.com, 14 March 2009. [Online].

Ahuja P, Sdek P, Maclellan WR, Cardiac myocyte cell cycle control in development, disease and regeneration. Physiol Rev 2007, 87: 521-544.

http://dx.doi.org/10.1152/physrev.00032.2006

PMid:17429040 PMCid:PMC2708177

Todd R, Wong DT: Oncogenes. Anticancer Res 1999, 19: 4729–4746.

PMid:10697588

Sherr CJ: Principles of tumor suppression. Cell 2004, 116: 235–246.

http://dx.doi.org/10.1016/S0092-8674(03)01075-4

Klein CA: Cancer. The metastasis cascade. Science 2008, 321: 1785–1787.

http://dx.doi.org/10.1126/science.1164853

PMid:18818347

Chiang AC, Massagué J: Molecular basis of metastasis. N Eng J Med 2008, 359:. 2814–2823.

http://dx.doi.org/10.1056/NEJMra0805239

PMid:19109576

Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, Raab-Tarub N, Roizman B: Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol. 2004, 14: 453–471.

http://dx.doi.org/10.1016/j.semcancer.2004.06.009

PMid:15489139

Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Eng J Med 2008, 359: 1367–1380.

http://dx.doi.org/10.1056/NEJMra0802714

PMid:18815398

Rueth NM, Andrade RS: Is VATS lobectomy better: perioperatively, biologically and oncologically? Annals of Thoracic Surgery 2010, 89: S2107–S2111

http://dx.doi.org/10.1016/j.athoracsur.2010.03.020

PMid:20493991

Goldstein SD, Yang SC: Role of surgery in small cell lung cancer. Surg Oncol Clin N Amer 2011, 20: 769–777.

http://dx.doi.org/10.1016/j.soc.2011.08.001

PMid:21986271

Le Péchoux C: Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011, 16: 672–681.

http://dx.doi.org/10.1634/theoncologist.2010-0150

PMid:21378080 PMCid:PMC3228187

NSCLC Meta-Analyses Collaborative Group. Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J. Clin. Oncol 2008, 26.

PMid:18165637

Kelley AS, Meier DE: Palliative care—a shifting paradigm. N Eng J Med 2010, 363: 781-782.

http://dx.doi.org/10.1056/NEJMe1004139

PMid:20818881

Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level. J Amer. Med. Assoc 2006, 295: 65–73.

http://dx.doi.org/10.1001/jama.295.1.65

PMid:16391218

Cillo U, Vitale A, Bassanello M, Boccagni P, Borelese A, Zanus G, Burra P, Fagiuoli S: Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann. Surg. 2003, 239: 150-159.

http://dx.doi.org/10.1097/01.sla.0000109146.72827.76

PMid:14745321 PMCid:PMC1356206

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, Oliviera A, Santoro A, Raoul J, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L: Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008, 359: 378–390.

http://dx.doi.org/10.1056/NEJMoa0708857

PMid:18650514

Chen M, Li J, Zheng Y, Guo R, Liang H, Zhang Y, Lin X, Lau W: A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma. Annal Surgery 2006, 243: 321–328.

http://dx.doi.org/10.1097/01.sla.0000201480.65519.b8

PMid:16495695 PMCid:PMC1448947

Vente MA, Wondergem M, van der Tweel I: Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009, 19: 951–959.

http://dx.doi.org/10.1007/s00330-008-1211-7

PMid:18989675

Bernstein LR, van der Hoeven JJ, Boer RO: Hepatocellular carcinoma detection by gallium scan and subsequent treatment with gallium maltolate: rationale and case study. Anti-Cancer Agents Med Chem 2011, 11: 585–590.

http://dx.doi.org/10.2174/187152011796011046

PMid:21554205

Yamamoto J, Suichi O, Kazuaki S, Takushi O, Susumu Y, Hideki U, Tomoo K: Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatol 2001, 34: 707–713.

http://dx.doi.org/10.1053/jhep.2001.27950

PMid:11584366

Reeder JG, Vogel VG: Breast cancer prevention. Cancer treatment res 2008, 141: 149–164.

http://dx.doi.org/10.1007/978-0-387-73161-2_10

PMid:18274088

Yager JD: Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354: 270–282.

http://dx.doi.org/10.1056/NEJMra050776

PMid:16421368

Gage M, Wattendorf D, Henry LR: Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol 2012, 105: 444–451

http://dx.doi.org/10.1002/jso.21856

PMid:22441895

Pasche B: Cancer Genetics (Cancer Treatment and Research), Berlin: Springer, 2010: 19-20.

http://dx.doi.org/10.1007/978-1-4419-6033-7

Holmes MD, Chen WY, Chen LL, Hertzmark E, Speigelman D, Hankinson SE: Aspirin Intake and Survival After Breast Cancer. J Clin Oncol 2010, 28: 1467–1472.

http://dx.doi.org/10.1200/JCO.2009.22.7918

PMid:20159825 PMCid:PMC2849768

Petit T, Dufour P, Tannock I: A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. Endocr. Relat. Cancer 2011, 18: R79–89.

http://dx.doi.org/10.1530/ERC-10-0162

PMid:21502311

Ahanzeb M: Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin. Breast Cancer 2008, 8: 324–333.

http://dx.doi.org/10.3816/CBC.2008.n.037

PMid:18757259

Belletti B, Vaidya JS, D'Andrea S: Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin. Cancer Res 2008, 14: 1325–1332.

http://dx.doi.org/10.1158/1078-0432.CCR-07-4453

PMid:18316551

Markowitz SD, Bertagnolli MM: Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer. N. Engl. J. Med 2009, 361: 2449–2460.

http://dx.doi.org/10.1056/NEJMra0804588

PMid:20018966 PMCid:PMC2843693

Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004, 10: 789–799.

http://dx.doi.org/10.1038/nm1087

PMid:15286780

Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CL, Lewis LR: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487: 330–337.

http://dx.doi.org/10.1038/nature11252

PMid:22810696 PMCid:PMC3401966

Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N: Colorectal cancer. Lancet 2010, 375: 1030–1047.

http://dx.doi.org/10.1016/S0140-6736(10)60353-4

Chemotherapy of metastatic colorectal cancer. Prescrire Int 2010, 19: 219–224.

PMid:21180382

Wasserberg N, Kaufman HS: Palliation of colorectal cancer. Surg Oncol 2007, 16: 299–310.

http://dx.doi.org/10.1016/j.suronc.2007.08.008

PMid:17913495

Dennis LK, Coughlin JA, McKinnon BC, Wells TS, Gaydos CA, Hamsikova E, Gray GC: Sexually transmitted infections and prostate cancer among men in the U.S. military Cancer epidemiology, biomarkers & prevention. Amer Assoc cancer Res 2009, 18: 2665-2671.

Leav I, Plescia J, Goel HL, Li J, Jiang Z, Cohen RJ, Languino LR, Altieri DC. Cytoprotective Mitochondrial Chaperone TRAP-1 As a Novel Molecular Target in Localized and Metastatic Prostate Cancer. Am. J. Pathol. 2010, 176: 393–401.

http://dx.doi.org/10.2353/ajpath.2010.090521

PMid:19948822 PMCid:PMC2797899

Zha J, Huang YF: TGF-beta/Smad in prostate cancer: an update. Zhonghua Nan Ke Xue 2009, 15: 840–843.

PMid:19947572

Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, Batra SK: Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK–RhoA signaling pathway. Oncogene 2010, 29: 1293–1302.

http://dx.doi.org/10.1038/onc.2009.420

PMid:19946339 PMCid:PMC2896817

Hong H, Zhang Y, Sun J, Cai W: Positron emission tomography imaging of prostate cancer. Amino Acids 2009, 39: 11–27.

http://dx.doi.org/10.1007/s00726-009-0394-9

PMid:19946787 PMCid:PMC2883014

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P: Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 2011, 31: 813–828.

http://dx.doi.org/10.1592/phco.31.8.813

PMid:21923608

Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R, Leibovitch I: Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. Jour Urol 2009, 182: 1313–1317.

http://dx.doi.org/10.1016/j.juro.2009.06.017

PMid:19683278

Halachmi S, Moskovitz B, Maffezzini M et al: Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol 2009, 29: 259–264.

http://dx.doi.org/10.1016/j.urolonc.2009.02.012

PMid:19395285

Majid S , Saini S, Dahiya R: Wnt signaling pathways in urological cancers: past decades and still growing.Review. Mol Cancer 2012, 11:7 doi: 10.1186/1476-4598-11-7.

http://dx.doi.org/10.1186/1476-4598-11-7

Sanchez-Carvayo M, Capodieci P, Cordon-Cardo C . Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol 2003, 162: 609-617.

http://dx.doi.org/10.1016/S0002-9440(10)63854-0

Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H, Guo X, Garcia EL, Michurina TV, Enikopolov G, Muthuswamy SK, Mills AA: Np63 alpha Is an Oncogene that Targets Chromatin Remodeler Lsh to Drive Skin Stem Cell Proliferation and Tumorgenesis. Cell Stem Cell 2011, 8: 164-176.

http://dx.doi.org/10.1016/j.stem.2010.12.009

PMid:21295273

"What causes melanoma skin cancer?" http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-what-causes," [Online].

Lind MH, Rozell B, and Walin RPA et al: Tumor necrosis factor receptor 1 mediated signaling is required for skin cancer development induced by NF-kB inhibition. PNAS 2004, 101: 4972-4977.

http://dx.doi.org/10.1073/pnas.0307106101

PMid:15044707 PMCid:PMC387358

Panelos J, Massi D: Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol Ther 2009, 8: 1986-1993.

http://dx.doi.org/10.4161/cbt.8.21.9921

PMid:19783903

Doherty GM, Gerard M, Mulholland MW: Greenfield's Surgery: Scientific Principles And Practice. Baltimore: Williams & Wilkins ISBN 0-7817-5626-X., 2005.

Furge KA, Tan MH, Dykema K et al: Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenic approach based on gene expression profiling. Review. Oncogene 2007, 26: 1346-1350

http://dx.doi.org/10.1038/sj.onc.1210256

PMid:17322920

Jonasch E, Messner C: CancerCare Connect - Treatment Update: Kidney Cancer," Cancer Care, Inc, 2012.

Advanced kidney cancer : Cancer Research UK : CancerHelp UK.

Niederacher D, An HX, Cho YJ, Hantschmann P, Bender HG, Beckmann MW: Mutations and amplification of oncogenes in endometrial cancer. Oncol 1999, 5: 6596-6565.

Kim TH, Lee DK, Cho SN, Orvis GD, Behringer RR, Lydon JP, Ku BJ, McCampbell AA, Broadddus RR, Jeong JW. Critical Tumor Suppressor Function Mediated by Epithelial Mig-6 in Endometrial Cancer. Cancer Res 2013, 73: 5090-5099.

http://dx.doi.org/10.1158/0008-5472.CAN-13-0241

PMid:23811943

Yamazawa K, Shimada H, Hirai M, Hirashiki K, Ochiai T, Ishikura H, Shozu M, Isaka K: Serum p53 antibody as a diagnostic marker of high-risk endometrial cancer. American journal of obstetrics and gynecology 2007, 197:505. e501-505. e507.

http://dx.doi.org/10.1016/j.ajog.2007.04.033

" Uterine Sarcomas - Hormonal Therapy," American Cancer Society, 2007.

Freeman JW, DeArmond D, Lake M, Huang W, Venkatasubbarao K, Zhao S: Alterations of cell signaling pathways in pancreatic cancer. Front Biosci 2004, 9: 1889-1998

http://dx.doi.org/10.2741/1388

PMid:14977595

Eser S, Reiff N, Messer M et al: Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer. Cancer Cell 2013, 23: 406-420.

http://dx.doi.org/10.1016/j.ccr.2013.01.023

PMid:23453624

Corbo V, Tortora G, Scarpa A: Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets 2012, 13: 744-752.

http://dx.doi.org/10.2174/138945012800564103

PMid:22458520 PMCid:PMC3419918

Neoptolemos JP, Stocken DD, Friess H et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350: 1200–1210.

http://dx.doi.org/10.1056/NEJMoa032295

PMid:15028824

Moore MJ, Goldstein D, Hamm J et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Clin Oncol 2007, 25: 1960-1966.

http://dx.doi.org/10.1200/JCO.2006.07.9525

PMid:17452677

Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS, Carbone M: Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 1996, 63: 37-50.

http://dx.doi.org/10.1002/(SICI)1097-4644(199610)63:1<37::AID-JCB3>3.0.CO;2-0

Kingsley LA, Fournier PJ, Chirgwin JM, Guise TA: Molecular Biology of Bone Metastasis. Mol Cancer Ther 2007, 6: 2609-2617.

http://dx.doi.org/10.1158/1535-7163.MCT-07-0234

PMid:17938257

Harris AL: Hypoxia - a key regulatory factor in tumour growth. Review. Nat Rev Cancer 2002, 2: 38-47.

http://dx.doi.org/10.1038/nrc704

PMid:11902584

FDA ANDA Generic Drug Approvals, Food and Drug Administration.

Chandana SR, Movva S, Arora M, Singh T: Primary Brain Tumors in Adults. Am Fam Physician 2008, 77: 1423-1430.

PMid:18533376

Steck PA, Saya H: Pathways of oncogenesis in primary brain tumors. Curr Opin Oncol 1991, 3: 4764-84.

http://dx.doi.org/10.1097/00001622-199106000-00006

"MD Anderson team identifies new oncogene for brain tumors". http://www.mdanderson.org/newsroom/news-releases/2007/m-d-anderson-team-identifies-new-oncogene-for-brain-tumors.html," 2007. [Online].

Shibuya M, Yamazaki H, Ohba Y, Fukui Y, Jeyama Y, Tamaoki N: Activation of Proto-Oncogenes in Human Brain Tumors. Biological Aspects of Brain Tumor, Springer 1991, 28-37.

http://dx.doi.org/10.1007/978-4-431-68150-2_3

Stockhausen MT, Kristoffersen K, Poulsen HS: Notch signaling and brain tumors. Adv Exp Med Bio 2012, 727: 289-304.

http://dx.doi.org/10.1007/978-1-4614-0899-4_22

PMid:22399356

Whole Brain Radiation increases risk of learning and memory problems in cancer patients with brain metastases, MD Anderson Cancer Center, 2012.

How Our Patients Perform : Glioblastoma Multiforme, UCLA Neuro-Oncology Program, 2012.

"Normal Pressure Hydrocephalus Causes, Symptoms, Treatment – Next Steps on eMedicineHealth," 2012. [Online]. Available: Emedicinehealth.com.

Ridanpää M, Lothe RA, Onfelt A, Børresen AL, Husgafvel-Pursiainen K: K-ras oncogene codon 12 point mutations in testicular cancer. Envl Health Pers 1993, 101 Suppl 3: 185-187.

Shyu RY, Wu CC, Wang CH, Tsai TC, Wang LK, Chen MK, Jiang SY, Tsai FM: H-rev107 regulates prostaglandin D2 synthase-mediated suppression of cellular invasion in testicular cancer cells. J Biomed Sci 2013, 20: 30.

http://dx.doi.org/10.1186/1423-0127-20-30

PMid:23687991 PMCid:PMC3669107

Vladusic T, Hrascan R, Pecina-Slau N, Vrhovac I, Gamulin M, Franekic J, Kruslin B: Loss of heterozygosity of CDKN2A (p16INK4a) and RB1 tumor suppressor genes in testicular germ cell tumors. Radiol Oncol 2010, 44: 168-173.

http://dx.doi.org/10.2478/v10019-010-0035-7

PMid:22933911 PMCid:PMC3423692

Boyer A, Paquet M, Laguë MN, Hermo L, Boerboom D: Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis. Carcinogenesis 2009, 30: 869-878, 2009.

http://dx.doi.org/10.1093/carcin/bgp051

PMid:19237610 PMCid:PMC2675650

Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A: Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gyn endoc 2011, 27: 597-604.

Yoon SK, Lim NK, Ha SA et al: The Human Cervical Cancer Oncogene Protein Is a New Biomarker for Human Hepatocellular Carcinoma. Cancer Res 2004, 64: 5434-5441.

http://dx.doi.org/10.1158/0008-5472.CAN-03-3665

PMid:15289352

Faridi R, Zahra A, Khan K, Idrees M: Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Review. Virol J 2011, 8: 269 doi: 10.1186/1743-422X-8-269.

http://dx.doi.org/10.1186/1743-422X-8-269

Erstad S: Cone biopsy (conization) for abnormal cervical cell changes," WebMD, 2007.

Plante M, Renaud MC, Hoskins IA, Roy M: Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol. Oncol. 2005, 98: 3–10.

http://dx.doi.org/10.1016/j.ygyno.2005.04.014

PMid:15936061

Veena MS, Lee G, Keppler D, Mendonca MS, Redpath J, Stanbridge EJ, Wilczynski SP, Srivatsan ES: Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. Genes Chromosomes Cancer. Genes Chromosomes Cancer 2008, 47: 740-754.

http://dx.doi.org/10.1002/gcc.20576

PMid:18506750 PMCid:PMC2974630

Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D: The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 2003, 9: 2981-2984.

PMid:12912945

Maity G, Fahreen S, Banerji A, Roy Choudhury P, Sen T, Dutta A, Chatterjee A: Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). Mol Cell Biochem 2010, 336: 65-74.

http://dx.doi.org/10.1007/s11010-009-0256-5

PMid:19816757

Shin WS, Kwon J, Lee HW et al: Oncogenic role of protein tyrosine kinase 7 in esophageal squamous cell carcinoma. Cancer Sci 2013, 104: 1120–1126.

http://dx.doi.org/10.1111/cas.12194

PMid:23663482

Rousseau MC, Hsu RY, Spicer JD, McDonald B, Chan CH, Perera RM, Giannias B, Chow SC, Rousseau S, Law S, Ferri LE: Lipopolysaccharide-induced toll-like receptor 4 signaling enhances the migratory ability of human esophageal cancer cells in a selectin-dependent manner. Surgery 2013, 154: 69-77.

http://dx.doi.org/10.1016/j.surg.2013.03.006

PMid:23809486

Sui G, Bonde P, Dhara S, Broor A, Wang J, Marti G: Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model. J Surg Res 2006, 134: 1-9.

http://dx.doi.org/10.1016/j.jss.2005.12.029

PMid:16488438

Li B, Li YY, Tsao SW et al: Targeting NF-κB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther 2009, 8: 2635-2644.

http://dx.doi.org/10.1158/1535-7163.MCT-09-0162

PMid:19723887

Pouw RE, Wirths K, Bergman JJ et al: Efficacy of Radiofrequency Ablation Combined with Endoscopic Resection for Barrett's Esophagus with Early Neoplasia. Clinl Gastroent Hepatol 2010, 8: 23-30.

http://dx.doi.org/10.1016/j.cgh.2009.07.003

PMid:19602454

Enger E, Ross F, Bailey D: Concepts in Biology, 14 ed., McGraw-Hill, 2011.

Kleinman HK, Liau G: Gene therapy for antiangiogenesis. J. Natl. Cancer Inst 2001, 93: 965–967.

http://dx.doi.org/10.1093/jnci/93.13.965

PMid:11438554

Tree AC, Khoo VS, Eeles RA; Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, as Van NJ: Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013, 14: e28-37

http://dx.doi.org/10.1016/S1470-2045(12)70510-7

Masihi KN: Fighting infection using immunomodulatory agents. Expert Opin Biol Ther 2001, 1: 641-653.

http://dx.doi.org/10.1517/14712598.1.4.641

PMid:11727500

Tongyoo A: Targeted therapy: novel agents against cancer. J Med Assoc Thai 2010, 93 Suppl 7, S311-23.

PMid:21294432

Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD: Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 2011, 17: 512-527.

http://dx.doi.org/10.1097/PPO.0b013e31823e701a

PMid:22157296 PMCid:PMC3381956

Kassouf W, Brown GA, Black PC, Fisher MB, Inamoto T, Luongo T: Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol 2008, 180: 1146-53.

http://dx.doi.org/10.1016/j.juro.2008.05.001

PMid:18639280

Brahmer JR, Tykodi SS, Chow LQ et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Eng J Med 2012, 366: 2455-2465.

http://dx.doi.org/10.1056/NEJMoa1200694

PMid:22658128 PMCid:PMC3563263

Jacobs MA, Wotkowicz C, Baumgart ED, Neto BS, Rieger-Christ KM, Bernier T: Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib. J Urol 2007, 178: 1510-1514.

http://dx.doi.org/10.1016/j.juro.2007.05.113

PMid:17707060

Yang JL, Qu XJ, Hayes VM, Brenner PC, Russell PJ, Goldstein D: Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. BJU Int 2007, 99: 1539-1545.

http://dx.doi.org/10.1111/j.1464-410X.2007.06778.x

PMid:17346275

Hodi FS, Mihm MC, Soiffer RJ et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. PNAS 2003, 100: 4712-4717

http://dx.doi.org/10.1073/pnas.0830997100

PMid:12682289 PMCid:PMC153621

Erivedge (vismodegib) package insert. [Performance]. Genentech, South San Francisco CA, 2012.

Yervoy (ipilimumab) package insert. [Performance]. Bristol-Myers Squibb, Princeton NJ, 2011.

De Smaele E, Ferretti E, Gulino A: Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010, 11:707-718.

PMid:20496266

(ClinicalTrials.gov Identifier:NCT01271972).

"http://investor.regeneron.com/releasedetail.cfm ReleaseID=737801," [Online].

Bargou R, Leo E, Zugmaier G et al: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 15: 974-977.

http://dx.doi.org/10.1126/science.1158545

PMid:18703743

Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP: A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res 2007, 13: 1810–1815.

http://dx.doi.org/10.1158/1078-0432.CCR-06-2318

PMid:17363537

Thakur A, Vaishampayan U, Lawrence G: Immunotherapy and Immune Evasion in Prostate Cancer. Cancers 2013, 5: 569-590.

http://dx.doi.org/10.3390/cancers5020569

PMCid:PMC3730318

Gabrilovich DI: Myeloid-derived suppressor cells and tumor microenvironment. J. Immunother 2009, 32: 987–988.

Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM: Gemcitabine selectively eliminates splenic Gr-1(+)/CD11b(+) myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res 2005, 11: 6713–6721.

http://dx.doi.org/10.1158/1078-0432.CCR-05-0883

PMid:16166452

Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD: Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009, 9: 900-909.

http://dx.doi.org/10.1016/j.intimp.2009.03.015

PMid:19336265

Clinical trials of Oncoerythyreon using tecemotide http://www.oncothyreon.com/clinical/Tecemotide.html

Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T: INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011, 11: doi: 10.1186/1471-2407-11-430.

http://dx.doi.org/10.1186/1471-2407-11-430

Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM: Translating Tumor Antigens into Cancer Vaccines. Clin Vacc Immunol 2011, 18: 23-24.

http://dx.doi.org/10.1128/CVI.00286-10

PMid:21048000 PMCid:PMC3019775

de Cerio AL, Zabalegui N, Rodgriguez-Calvillo M, Inoges S, Bendandi M: Anti-idiotype antibodies in cancer treatment. Oncogene 2007, 26: 3594-3602.

http://dx.doi.org/10.1038/sj.onc.1210371

PMid:17530013

Palucka K, Banchereau J: Dendritic-Cell-Based Therapeutic Cancer Vaccines. Immunity 2013, 39: 38-48.

http://dx.doi.org/10.1016/j.immuni.2013.07.004

PMid:23890062

Stevenson FK, Ottensmeier CH, Johnson PEA: DNA vaccines to attack cancer. PNAS 2004, 101 Suppl 2: 14646-14652.

http://dx.doi.org/10.1073/pnas.0404896101

PMid:15292504 PMCid:PMC521995

Teshima T, Mach N, Hill GR et al: Tumor Cell Vaccine Elicits Potent Antitumor Immunity after Allogeneic T-Cell-depleted Bone Marrow Transplantation. Cancer res 2001, 61: 162–171.

PMid:11196155

Nemunaitis J: Oncolytic viruses. Investigational new drugs 1999, 17: 375–386.

http://dx.doi.org/10.1023/A:1006334404767

PMid:10759404

Melcher A, Parato K, Rooney CM, Bell JC: Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide. Mol Ther 2011, 19: 1008–1016.

http://dx.doi.org/10.1038/mt.2011.65

PMid:21505424 PMCid:PMC3129809

Meerani S, Yao Y: Oncolytic Viruses in Cancer Therapy. Eur J Sci Res 2010, 40: 156 -171.

Bourke MG, Salwa S, Harrington KJ, Kucharczyk MJ, Forde PF, de Kruijf M, Soden D, Tangney M, Collins JK, O' Sullivan GC: The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 2011, 37: 618-632.

http://dx.doi.org/10.1016/j.ctrv.2010.12.003

PMid:21232872

MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM: Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991, 72: 631-639.

http://dx.doi.org/10.1099/0022-1317-72-3-631

PMid:1848598

Braidwood L, Dunn PD et al: Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. Anticancer Res 2009, 29: 2159-2166.

PMid:19528476

MacKie RM, Stewart B, Brown SM: Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. The Lancet 2011, 357: 525-526.

http://dx.doi.org/10.1016/S0140-6736(00)04048-4

Mace AT, Ganly I et al: Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head & Neck 2008, 30: 1045-1051.

http://dx.doi.org/10.1002/hed.20840

PMid:18615711

Garber K: China Approves World's First Oncolytic Virus Therapy for Cancer Treatment. J Nat Cancer Inst 2006, 98: 298–300.

http://dx.doi.org/10.1093/jnci/djj111

PMid:16507823

"Gene Therapy," MD Anderson, [Online]. Available: http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-topics/cancer-treatment/chemotherapy/gene-therapy/index.html.

Kershaw MH, Westwood JA, Darcy PK: Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013, 13: 525-541.

http://dx.doi.org/10.1038/nrc3565

PMid:23880905

Heslop HE: Genetic engineering of T-cell receptors: TCR takes to titin. Blood 2013, 122: 853-854.

http://dx.doi.org/10.1182/blood-2013-06-509604

PMid:23929832

Huang TT, Hlavaty J, Ostertag D, Espinoza FL et al: Toca 511 gene transfer and 5-fluorocytosine in combination of temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide sensitive glioblastoma model. Cancer Gene Ther 2013.

http://dx.doi.org/10.1038/cgt.2013.51

Starlard-Davenport A, Kutanzi K, Tryndyak V, Word B, Lyn-Cook B: Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: A novel epigenetic therapeutic approach. J. Carcinogenesis 2013, 12:15.

http://dx.doi.org/10.4103/1477-3163.115720

PMid:23961262 PMCid:PMC3746452

"What Is Cancer Screening?," National Cancer Institute, [Online]. Available: http://www.cancer.gov/cancertopics/screening.

Wilson JM, Jungner G: Principles and practice of screening for disease. World Health Organization. Public Health Papers, #34, 1968.

Morgan JE, Carr IM, Sheridan E et al: Genetic diagnosis of familial breast cancer using clonal sequencing. Hum mutat 2010, 31: 484-491.

http://dx.doi.org/10.1002/humu.21216

PMid:20127978

Meldrum C, Doyle MA, Tothill RW: Next-Generation Sequencing for Cancer Diagnostics: a Practical Perspective. Review. Clin Biochem Rev 2011, 32: 177-195.

PMid:22147957 PMCid:PMC3219767

Narayan A, Carriero NJ, Gettinger SN, et al: Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing. Cancer Res 2012, 72: 3492-3498.

http://dx.doi.org/10.1158/0008-5472.CAN-11-4037

PMid:22581825 PMCid:PMC3426449

Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW: BEAMing up for detection and quantification of rare sequence variants. Nat methods 2006, 3: 95-97.

http://dx.doi.org/10.1038/nmeth850

PMid:16432518

Screening for Cervical Cancer, U.S. Preventive Services Task Force, March 2012. [Online]. Available: http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerfact.pdf.

Tonus C, Sellinger M: Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: A meta-analysis. World J Gastroent 2012, 18: 4004-4011.

http://dx.doi.org/10.3748/wjg.v18.i30.4004

PMid:22912551 PMCid:PMC3419997

Ahrens M J, Bertin PA, Vonesh EF, Meade TJ, Catalona WJ, Georganopoulou D: PSA enzymatic activity: A new biomarker for assessing prostate cancer aggressiveness. Prostate 2013, doi: 10.1002/pros.22714.

http://dx.doi.org/10.1002/pros.22714

Jacklitsch MT, Jacobson FL, Austin JHM, Field JK et al: The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac cardiovas Surg 2012, 144: 33-38

"Jack Andraka the teen prodigy of pancreatic cancer," Smithsonian Magazine, 2012. [Online]. Available: http://www.smithsonianmag.com/science-nature/Jack-Andraka-the-Teen-Prodigy-of-Pancreatic-Cancer-179996151.html.

"Circulating Mesothelin Serves as a Marker of Pancreatic Cancer," 22 October 2009. [Online]. Available: http://phys.org/news175447210.html.

Johnston FM, Tan MC B, Tan Jr BR, Porembka MR, et al: Circulating Mesothelin Protein and Cellular anti-Mesothelin Immunity in Patients with Pancreatic Cancer. Clin Cancer Res 2009, 15: 6511-6518.

http://dx.doi.org/10.1158/1078-0432.CCR-09-0565

PMid:19843662 PMCid:PMC2782601

Polanski M, Leigh Anderson N: A list of candidate cancer biomarkers for targeted proteomics. Review. Biomarker Insights 2006, 2:1-48.

Hanausek M, Walaszek Z, Slaga TJ: Detoxifying cancer causing agents to prevent cancer. Integr Cancer Ther 2003, 2: 139-144.

http://dx.doi.org/10.1177/1534735403002002005

PMid:15035900

Zhao B, Wang Y, Wu B: Placenta-derived gp96 as a multivalent prophylactic cancer vaccine. Scientific reports 2013, 3: 1-7.

Yaddanapudi K, Robert A, Putty MK, Willer S, Sharma RK, Yan J, Bodduluri H, Eaton JW: Vaccination with Embryonic Stem Cells Protects against Lung Cancer: Is a Broad-Spectrum Prophylactic Vaccine against Caner possible? PLoS One 2012, 7: 1-12.

http://dx.doi.org/10.1371/journal.pone.0042289

PMid:22860107 PMCid:PMC3409174

Waknine Y: International Approvals: Singulair and Gardasil/Silgard," Medscape Today, 2008.

Lowy DR, Schiller JT: Prophylactic human papillomavirus vaccines. J. Clin. Invest 2006, 116: 1167–1173.

http://dx.doi.org/10.1172/JCI28607

PMid:16670757 PMCid:PMC1451224

Gardasil Vaccine Safety. Vaccine Safety & Availability," U.S. Food and Drug Administration (FDA), 2009.




DOI: http://dx.doi.org/10.14259%2Fcs.v1i2.64

Refbacks

  • There are currently no refbacks.